PMID- 33450398
OWN - NLM
STAT- MEDLINE
DCOM- 20210910
LR  - 20220716
IS  - 1534-4436 (Electronic)
IS  - 1081-1206 (Print)
IS  - 1081-1206 (Linking)
VI  - 127
IP  - 1
DP  - 2021 Jul
TI  - The use of microarray and other multiplex technologies in the diagnosis of 
      allergy.
PG  - 10-18
LID - S1081-1206(21)00003-X [pii]
LID - 10.1016/j.anai.2021.01.003 [doi]
AB  - OBJECTIVE: To give an overview and describe the strengths and weaknesses of 
      immunoglobulin E (IgE) microarray and other multiplex assays that have been 
      developed and are being used for allergy diagnostics. DATA SOURCES: Queries for 
      IgE microarray and multiplex assays were conducted with PubMed and Google 
      Scholar, searching for primary articles and review papers. STUDY SELECTIONS: We 
      focused on articles written in English on commercially available IgE multiplex 
      assays that were reported in the allergy and immunology literature. RESULTS: 
      Several commercial IgE assays that use microarray or other multiplex technology 
      have been developed, and some have been implemented into clinical practice in 
      Europe and Asia, with the Immuno Solid-Phase Allergen Chip being the most widely 
      studied. Results of these assays generally correlate with results using 
      "singleplex" IgE assays (eg, ImmunoCAP), though there can be variability among 
      products and among allergens. A strength of the microarray technology is that IgE 
      to a large number of allergens can be detected simultaneously in a single test, 
      and only a small amount of patient serum is required. Cost, inadequate 
      sensitivity under some scenarios, and difficulties with data interpretation, in 
      some cases of 100 or more allergens, can be limitations. CONCLUSION: IgE 
      microarray assays are already a valuable tool in research applications. These 
      assays, and also other forms of IgE multiplex assays, are likely to play an 
      important role in the clinical practice of allergy in the future. Additional 
      studies focused on clinical outcomes, and the development of more targeted 
      allergen panels could facilitate increased clinical use.
CI  - Copyright (c) 2021 American College of Allergy, Asthma & Immunology. Published by 
      Elsevier Inc. All rights reserved.
FAU - Keshavarz, Behnam
AU  - Keshavarz B
AD  - Division of Allergy and Immunology, Department of Medicine, University of 
      Virginia, Charlottesville, Virginia.
FAU - Platts-Mills, Thomas A E
AU  - Platts-Mills TAE
AD  - Division of Allergy and Immunology, Department of Medicine, University of 
      Virginia, Charlottesville, Virginia.
FAU - Wilson, Jeffrey M
AU  - Wilson JM
AD  - Division of Allergy and Immunology, Department of Medicine, University of 
      Virginia, Charlottesville, Virginia. Electronic address: jmw2gc@virginia.edu.
LA  - eng
GR  - R37 AI020565/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20210112
PL  - United States
TA  - Ann Allergy Asthma Immunol
JT  - Annals of allergy, asthma & immunology : official publication of the American 
      College of Allergy, Asthma, & Immunology
JID - 9503580
RN  - 0 (Allergens)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Allergens/immunology
MH  - Humans
MH  - Hypersensitivity/*diagnosis/*immunology
MH  - Immunoglobulin E/*immunology
MH  - Immunologic Tests
MH  - Microarray Analysis/*methods
MH  - Technology Assessment, Biomedical
PMC - PMC9107268
MID - NIHMS1662233
EDAT- 2021/01/16 06:00
MHDA- 2021/09/11 06:00
PMCR- 2022/07/01
CRDT- 2021/01/15 20:10
PHST- 2020/11/03 00:00 [received]
PHST- 2020/12/18 00:00 [revised]
PHST- 2021/01/04 00:00 [accepted]
PHST- 2021/01/16 06:00 [pubmed]
PHST- 2021/09/11 06:00 [medline]
PHST- 2021/01/15 20:10 [entrez]
PHST- 2022/07/01 00:00 [pmc-release]
AID - S1081-1206(21)00003-X [pii]
AID - 10.1016/j.anai.2021.01.003 [doi]
PST - ppublish
SO  - Ann Allergy Asthma Immunol. 2021 Jul;127(1):10-18. doi: 
      10.1016/j.anai.2021.01.003. Epub 2021 Jan 12.